Source of the article:Heart NotCome;Editor:Huang ChuyanReprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.On November 2, 2023, Inari Medical (NASDAQ: NARI) announced that it has entered into a definitive agreement to acquire LimFlow SA for up to $415 million.# Inari Medical Acquires LimFlow Medical
As forWeeks before this deal, LimFlow's treatment for chronic limb-threatening ischemia (CLTI)Breakthrough System Receives FDA Pre-Market Approval（PMA）。Inari Medical stated that the acquisition is expected to be completed by the end of 2023.Inari Medical will pay $250 million in cash upon the completion of the transaction and up to $165 million based on certain commercial and reimbursement milestones.Inari MedicalCEO Drew Hykes stated:"The acquisition of LimFlow is closely aligned with our mission to address significant unmet patient needs and adds to our product portfolio."Another highly differentiated growth platform.”
Hykes said in the press release, "We believe the CLTI market is poised for sustained growth, driven by compelling technology, excellent clinical outcomes, and multiple expansion opportunities. Since early 2022, as a minority investor in LimFlow and a board observer, we have witnessed firsthand the impact of this technology in transforming patients' lives, as well as the complementary nature of our two companies."Other investors in LimFlow include Sofinnova Partners, Bpifrance, Balestier (an affiliate of M&L Healthcare Investments), Longitude Capital, and Soleus Capital.Dr. Martin Rothman and Tim Lenihan co-founded LimFlow and incubated it through MD Start.LimFlow CEO Dan Rose said in a press release, "We are thrilled to partner with Inari Medical to expand the reach of our groundbreaking technology and bring new hope to patients currently suffering. We sincerely thank the exceptional LimFlow team, dedicated clinical partners, and investors who have placed their trust in us. We eagerly look forward to advancing our shared vision to address unmet critical needs in the field of vascular disease."# About LimFlow System
LimFlow System is a minimally invasive technology designed to divert blood around diseased arteries in the patient's leg and deliver it into the tibial veins that supply blood to the foot, thereby delivering blood and oxygen to ischemic and hypoxic tissues in the foot. The abundant oxygen in the tissues can immediately relieve pain and promote chronic wound healing in most patients, improving their quality of life and restoring their confidence in life.The LimFlow System includes an endoluminal ultrasound catheter (arterial, venous) kit and an ultrasound monitoring system;VeinValveKnife;Matching self-expanding covered stent (Including conical stent grafts and straight stent grafts)。Through venous access at the ankle or sole, puncture from the arterial to the venous segment under ultrasound guidance. Use a push-valve knife to retract and remove the venous valve, place a straight-extending stent graft in the venous segment, and then place a tapered crossover stent graft distal to the stent graft into the arterial segment.
# About LimFlow SA
LimFlow SA is a medical technology company headquartered in France, focusing on developing and promoting innovative technologies for the treatment of chronic limb-threatening ischemia (CLTI). The company's core product is an interventional device named the "LimFlow System."
LimFlow SA is committed to advancing the development and application of the LimFlow System through clinical research and partnerships. The company collaborates with medical institutions worldwide to conduct clinical trials assessing the safety and efficacy of the technology. LimFlow SA also partners with other medical device companies to drive innovation in the field of chronic limb-threatening ischemia.
# About Inari Medical
Inari Medical was founded in July 2011 in Delaware, with its headquarters located in Irvine, California. It is a commercial-stage medical device company dedicated to the development, manufacturing, and sales of interventional treatment devices for venous diseases. In May 2020, Inari Medical went public on the NASDAQ Stock Exchange in the United States under the stock ticker NARI, with Bank of America and Morgan Stanley serving as the joint book-running managers for the transaction.Inari Medical focuses on developing innovative catheter-based technologies to treat venous thromboembolism, aiming to safely remove large amounts of clot from major blood vessels without the use of thrombolytic drugs. Inari Medical has developed two minimally invasive, mechanical thrombectomy technology platforms: Flow Triever and Clot Triever. Clot Triever is used to remove clots from peripheral blood vessels and treat patients with deep vein thrombosis, while Flow Triever is used to treat pulmonary embolism.
Overseas Cardiovascular Devices:
Artivion | Abbott | Shockwave Medical | HVR Cardio | Abiomed |CardiacSense | Lydus Medical | Volta Medical |Cardiac Dimensions | HeartBeam | MedtronicRadiant | MedtronicAcQCross | Acutus Medical | Boston Scientific | Cardiovascular Systems | CVRx | Biotronik | Edwards Lifesciences |Cordis
Products of Chinese Cardiovascular Companies:
Huamai Taik Technology | Heartpulse Medical | Baxinan | Venus Medtech | Lepu Medical | Lifetech Scientific | Minimally Invasive Medical | Baren Medical |
